CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 1, 2009--
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a biotechnology company
engaged in the discovery and development of DNA- and RNA-based drug
candidates targeted to Toll-like Receptors (TLR), today announced that
it will discuss its drug discovery and development programs and provide
a general corporate overview at the 11th Annual Massachusetts
Biotechnology Investors Forum on Tuesday, October 6, 2009, at 3:40 p.m.
(ET) at the Sheraton Hotel in Boston.
About Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals develops drug candidates to treat infectious
diseases, autoimmune and inflammatory diseases, cancer, and respiratory
diseases, and for use as vaccine adjuvants. Our proprietary drug
candidates are designed to modulate specific Toll-like Receptors, which
are a family of immune system receptors that direct immune system
responses. Our pioneering DNA and RNA chemistry expertise enables us to
create drug candidates for internal development and generates
opportunities for multiple collaborative alliances. For more
information, visit www.iderapharma.com.
Idera Forward Looking Statements
This press release contains forward-looking statements concerning Idera
Pharmaceuticals, Inc. that involve a number of risks and uncertainties.
For this purpose, any statements contained herein that are not
statements of historical fact may be deemed to be forward-looking
statements. Without limiting the foregoing, the words "believes,"
"anticipates," "plans," "expects," "estimates," "intends," "should,"
"could," "will," "may," and similar expressions are intended to identify
forward-looking statements. There are a number of important factors that
could cause the Company’s actual results to differ materially from those
indicated by such forward-looking statements, including whether products
based on the Company’s technology will advance into or through the
clinical trial process on a timely basis or at all and receive approval
from the United States Food and Drug Administration or equivalent
foreign regulatory agencies; whether, if the Company’s products receive
approval, they will be successfully distributed and marketed; whether
the Company’s cash resources will be sufficient to fund the its
operations; and such other important factors as are set forth under the
caption "Risk Factors" in the Company’s Quarterly Report on Form 10-Q
for the three months ended June 30, 2009, which important factors are
incorporated herein by reference. The Company disclaims any intention or
obligation to update any forward-looking statements.
Source: Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc.
Kelly Luethje, 617-679-5519
kluethje@iderapharma.com
or
MacDougall
Biomedical Communications
Chris Erdman, 781-235-3060
cerdman@macbiocom.com
